Urology · Englewood, FL
NPI
1992989776
Since 2007
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2061 Englewood Rd, Suite 3a
Englewood, FL, 34223
Phone (941) 474-4061
Groups this clinician bills Medicare through
Medicare paid, 2024
$390K
6,178 services
Medicare patients, 2024
1,426
Average age 76
Drug cost, 2024
$545K
5,438 prescriptions
Company payments, 2023
$432
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Scott T Martz was code 99214 (office e&m - established), 1,549 times for 1,012 patients. In total Scott T Martz billed 6,178 services in 69 codes, and Medicare paid $390K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-11-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,549 | 1,012 | $92.13 | $143K |
| 81003 Clinical Chemistry | Office | 1,437 | 1,031 | $2.20 | $3,161 |
| 51798 Ultrasound - Nonspecific | Office | 680 | 499 | $7.96 | $5,412 |
| 99213 Office E&M - Established | Office | 298 | 252 | $63.26 | $19K |
| 99204 Office E&M - New | Office | 286 | 285 | $116.88 | $33K |
| 52000 Cystourethroscopy | Office | 283 | 231 | $175.53 | $50K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 246 | 31 | $141.80 | $35K |
| 99233 Hospital E&M - Subsequent | Facility | 138 | 61 | $92.48 | $13K |
| 99211 Office E&M - Established | Office | 93 | 46 | $16.20 | $1,507 |
| 74420 Standard X-ray | Facility | 92 | 67 | $18.69 | $1,720 |
| 51741 Test - Miscellaneous | Office | 63 | 62 | $9.33 | $588 |
| 99223 Hospital E&M - Initial | Facility | 61 | 60 | $131.84 | $8,042 |
| 52310 Calculus Removal - Urinary | Office | 48 | 48 | $232.76 | $11K |
| 52356 Calculus Removal - Urinary | Facility | 45 | 42 | $318.84 | $14K |
| 52332 Cystourethroscopy | Facility | 44 | 38 | $92.56 | $4,072 |
By year: 2022 $384K for 8,291 services; 2023 $382K for 6,795 services; 2024 $390K for 6,178 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,437 | 1,031 | $2.20 | $3,161 |
Medicare prescription drug claims, 2024
In 2024, the drug Scott T Martz prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,002 prescriptions and refills. In total Scott T Martz wrote 5,438 Medicare prescriptions that cost $545K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,002 | 2,518 | 374 | $13K |
| Alfuzosin Hcl Er Alfuzosin Hcl | 919 | 2,335 | 289 | $18K |
| Finasteride Generic | 834 | 2,058 | 244 | $8,805 |
| Myrbetriq Mirabegron | 398 | 724 | 114 | $324K |
| Silodosin Generic | 388 | 740 | 113 | $24K |
| Cephalexin Generic | 359 | 442 | 252 | $1,958 |
| Testosterone Cypionate Generic | 234 | 322 | 37 | $5,244 |
| Tramadol Hcl Generic | 203 | 203 | 154 | $344 |
| Potassium Citrate Er Potassium Citrate | 119 | 230 | 42 | $10K |
| Ciprofloxacin Hcl Generic | 103 | 103 | 90 | $447 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 89 | 103 | 70 | $348 |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 87 | 88 | 52 | $992 |
| Gemtesa Vibegron | 82 | 183 | 26 | $86K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 58 | 164 | 22 | $1,424 |
| Testosterone Generic | 54 | 61 | Under 11 | $4,729 |
Brand drugs: - claims; generic drugs: 4,881 claims; opioid claims: 210.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Scott T Martz $432 ($432 in general payments such as food, travel and fees) from 2 companies. The largest payer was KARL STORZ Endoscopy-America with $413.
| Company | Payments | Amount |
|---|---|---|
| KARL STORZ Endoscopy-America | 4 | $413 |
| Medtronic, Inc. MDT | 1 | $18.54 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.